CSL’s Paul McKenzie Out, as Gordon Naylor Named Interim CEO
CSL Limited announced that CEO Paul McKenzie will step down immediately after more than five years with the Australian biotech group. The board appointed Gordon Naylor, a veteran pharma executive, as interim chief executive. The decision reflects the board’s view that McKenzie lacked the skill set needed to navigate CSL’s current strategic challenges. Naylor will lead the company while a permanent successor is identified.
AstraZeneca’s Obesity Pill Hits in Phase 2, Key Cancer Trials Pushed Back
AstraZeneca announced that its oral GLP‑1 candidate elecoglipron achieved its primary efficacy endpoints in two Phase 2 obesity studies. The trials demonstrated statistically significant weight loss and a favorable safety profile, positioning the drug as a potential first‑in‑class oral therapy. Simultaneously,...
'Bat-Sh*t Crazy': Biopharma Leaders Unload on Regulatory Chaos
The provided excerpt contains only the title and a brief introductory sentence of an article about biopharma executives criticizing regulatory complexity, without the full body text. Consequently, no substantive details about specific comments, companies, regulatory issues, or market impacts are...
FDA Rejects Regenxbio's Hunter Syndrome Gene Therapy
The U.S. Food and Drug Administration has officially rejected Regenxbio's investigational gene therapy for Hunter syndrome, a severe X‑linked lysosomal storage disorder. The agency cited gaps in efficacy data and unresolved safety signals from the early‑stage clinical program. Regenxbio had...
With Scant Data, RFK Jr. Credits Trump for Higher European Drug Prices
Robert F. Kennedy Jr., serving as HHS Secretary, reiterated his claim that President Donald Trump's personal intervention and the threat of tariffs forced European nations to raise drug prices. He offered no empirical evidence to substantiate the assertion, and analysts...
QuantX Raises $85M Series B From Lilly, Sanofi Ventures
QuantX Biosciences, a China‑American biotech, announced an $85 million Series B financing round led by the venture arms of Eli Lilly and Sanofi. The capital will fund the company’s immunology pipeline, which targets several high‑profile immune‑modulating proteins. The round underscores growing pharma interest...
Despite FDA’s Crackdown, Pharma Is Still Spending Millions on Ads
The FDA launched an aggressive crackdown on pharmaceutical advertising last fall, issuing thousands of warning letters to drugmakers over misleading consumer ads. Despite the heightened scrutiny, the industry continued to pour roughly $2 billion into promotional campaigns, shifting spend toward digital...
Galux Raises $29M Series B; CSL Teams up with Memo
South Korean biotech Galux secured $29 million in a Series B round to accelerate its AI‑driven research platform that designs novel protein therapeutics. The funding, led by regional venture partners, will expand Galux’s computational pipeline and scale up pre‑clinical collaborations. In parallel,...
#ACTRIMS26: Roche’s MS Drug Fenebrutinib Beats Ocrevus, Cutting Risk of Disability Progression by 12%
Roche announced that its Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib achieved non‑inferior efficacy to the company’s blockbuster Ocrevus in a Phase 3 trial for primary progressive multiple sclerosis (PPMS). The oral agent lowered the risk of confirmed disability progression by 12%...
Takeda, Iambic Sign Multiyear R&D Deal for AI Drug Discovery
Takeda Pharmaceutical announced a multi‑year research agreement with San Diego biotech Iambic to develop AI‑driven small‑molecule drug candidates. The collaboration merges Takeda’s therapeutic expertise with Iambic’s generative AI platform to accelerate hit identification and lead optimization. Joint R&D labs, data...
Novo Nordisk Sues Hims over Wegovy Patent Infringement, Considers Seeking 'Hundreds of Millions' In Damages
Novo Nordisk has filed a federal lawsuit against Hims Inc., alleging that the company infringed on patents covering Wegovy, Novo's flagship semaglutide obesity treatment. The complaint seeks damages in the “hundreds of millions” of dollars, reflecting the high commercial stakes...
Lilly Returns to Innovent to Partner on Cancer and Immune Diseases
Eli Lilly has deepened its alliance with China‑based Innovent Biologics, signing a new agreement that includes a $350 million upfront payment. The partnership will focus on co‑developing bispecific antibody candidates targeting oncology and immunology indications. Both companies will share development costs, milestone...
#ACTRIMS26: Sanofi Unpacks Data From a Failed Phase 3 Tolebrutinib Trial in PPMS
Sanofi disclosed results from its Phase 3 trial of the BTK inhibitor tolebrutinib in primary progressive multiple sclerosis (PPMS). The study failed to meet its primary endpoint of slowing disability progression, and secondary outcomes showed no meaningful benefit. Safety data...
US Calls for DOJ Investigation of Hims over GLP-1 Drugs
The U.S. government has referred tele‑health firm Hims & Hers to the Department of Justice for a formal investigation into its GLP‑1 weight‑loss program. Hims, which recently launched a compounded version of GLP‑1 drugs to compete with Novo Nordisk’s market‑leading injectables, is...
TrumpRx Launch Falls Flat for some, Citing Generic Access
President Donald Trump unveiled TrumpRx, a direct‑to‑consumer drug platform promising to let Americans purchase prescription medicines without traditional insurance intermediaries. The rollout was framed as a fulfillment of broken political promises to lower drug costs. However, early feedback highlights that...
HHS Drops Legal Fight over Blocked 340B Rebate Pilot
The U.S. Department of Health and Human Services has abandoned its legal challenge to a federal court’s injunction that halted a proposed 340B drug‑price rebate pilot. The pilot, designed by the Trump administration to test new rebate mechanisms for hospitals...
Orphan Drug Tweak in US Spending Bill Will Make Life Easier for the FDA
President Donald Trump signed the federal spending bill preserving the FDA’s ability to grant a seven‑year exclusivity period for orphan drugs that receive new indications. The provision reverses earlier suggestions to shorten the exclusivity term, embedding the policy in the...
Agomab, SpyGlass Cap Biggest Week for Biotech IPOs Since 2021
Biotech IPO activity is rebounding as Agomab Therapeutics and SpyGlass Pharma launch public offerings on Friday. Agomab, a fibrosis‑focused company, aims to raise capital to advance its antibody candidates, while SpyGlass seeks funding for its eye‑disease pipeline. The combined debut...
UniQure Pauses Higher Doses in Fabry Study; Aro Shares Pompe Data
UniQure announced a pause on the mid‑ and high‑dose cohorts of its Fabry disease gene‑therapy trial after two participants receiving 4×10^13 genome copies per kilogram experienced safety concerns. The low‑dose arm will continue while the company conducts a detailed safety...
Geoff McDonough's Big Plans for NodThera's NLRP3; Enhertu Leader Steps Down at Daiichi
Former Generation Bio CEO Geoff McDonough has joined biotech NodThera to accelerate its NLRP3 inflammasome program, targeting a Phase 3 trial launch next year. The move underscores NodThera’s ambition to capture a fast‑growing market for anti‑inflammatory therapies. In parallel, Daiichi...
Roivant Spinout Priovant Touts Phase 2 Brepocitinib Data in Cutaneous Sarcoidosis
Priovant Therapeutics, a Roivant spin‑out, announced that brepocitinib – an experimental immune modulator inherited from Pfizer – achieved its primary efficacy endpoint in a Phase 2 trial for cutaneous sarcoidosis. The study demonstrated statistically significant reductions in skin lesion severity and...
Post-Hoc Live: Analyzing the Novo Vs. Hims GLP-1 Showdown
Post‑Hoc Live hosted a deep‑dive into the emerging rivalry between Novo Nordisk and Hims & Hers over GLP‑1 therapies. Novo, the long‑time market leader with drugs like Ozempic and Wegovy, faces a new challenger as Hims rolls out a lower‑priced...
Illumina Bets on Healthcare After Trump Administration's NIH Funding Disruptions
Illumina announced a strategic pivot toward healthcare customers after the Trump administration’s disruptions to NIH funding slashed research‑sector spending. The company will expand its clinical‑grade sequencing platforms, accelerate partnerships with diagnostic labs, and pursue new reimbursement pathways. Illumina projects its...
FDA Chief Makary Takes Aim at Hims' Compounded Wegovy Pill Plans
FDA Commissioner Marty Makary publicly warned Hims & Hers that the agency will act quickly against its plan to compound Wegovy, the popular semaglutide weight‑loss injection. The warning follows reports that the telehealth firm intends to sell a lower‑cost, compounded...
White House Launches TrumpRx
The White House unveiled TrumpRx, a new direct‑to‑consumer website that lets Americans compare prescription drug prices and find lower‑cost options. The platform pulls real‑time pricing data from pharmacies, insurers and manufacturers, and provides discount coupons and pharmacy locators. TrumpRx is...
Veradermics CEO Has a Great Hair Day with 122% Pop in IPO
Veradermics, a biotech developing an oral formulation of minoxidil, saw its shares soar 122% on the first day of trading. The company aims to capture the growing consumer demand for hair‑loss solutions, positioning its product as a convenient alternative to...
#ISC26: Bayer’s Asundexian Reduced Ischemic Strokes by 26% in Phase 3 Trial
Bayer announced that its next‑generation factor XIa inhibitor asundexian cut ischemic stroke incidence by 26% in a pivotal Phase 3 trial for secondary stroke prevention. The study also reported a favorable safety profile, with fewer major bleeding events compared with standard anticoagulants....
Bristol Myers Draws Pipeline Excitement as Several Data Readouts Near
Bristol Myers Squibb highlighted at least ten late‑stage data readouts slated for 2024, reigniting investor enthusiasm after a period of muted pipeline news. The readouts span oncology, immunology and rare disease programs, many of which could support new label extensions...
GLP-1s and the Super Bowl
Hims & Hers launched a new Super Bowl commercial promoting GLP‑1 weight‑loss drugs, positioning the brand amid a surge in public interest. The ad directly calls out disparities in healthcare access, contrasting affluent consumers’ ability to afford the medication with...
Thermo Fisher, Charles River Workforce Cuts; WuXi Signs Contract with Vertex
Thermo Fisher Scientific announced the closure of its chemical analysis manufacturing site in Franklin, Massachusetts, citing current customer demand shifts. The shutdown will affect the plant’s workforce, adding to a wave of staffing reductions across the life‑science services sector, including...
Telehealth Provider Hims Goes After Novo's Weight Loss Pill with Compounded Version
Hims & Hers announced it will begin selling a compounded version of Novo Nordisk's Wegovy weight‑loss injection on Thursday, just weeks after the FDA approved the brand‑name drug. The telehealth firm positions the lower‑cost alternative as a more accessible option...
Eikon IPO Analysis: Big Biotech Names, Big Valuation Cut
Eikon Therapeutics, a Bay Area biotech that has raised more than $1 billion, launched its initial public offering this week. The IPO was priced at a valuation significantly lower than the $2 billion range previously projected, reflecting a broader pullback in biotech...
Eisai Gains Henlius Therapy; LB Pharma Snags $100M in Funding
Eisai announced an exclusive commercial license with China’s Henlius to sell the anti‑PD‑1 antibody serplulimab in Japan. The agreement gives Eisai sole rights to market the immunotherapy, positioning it alongside the company’s existing oncology portfolio. Serplulimab, a checkpoint inhibitor, is...
Angitia Gets $130M Series D for Pipeline of Musculoskeletal Drugs
Angitia Biopharmaceuticals announced a $130 million Series D financing round, led by a consortium of U.S. and Chinese investors. The capital will fund three biologic candidates currently in clinical trials for musculoskeletal disorders. One candidate targets a disease where Ultragenyx recently reported...
Flagship's Generate:Biomedicines Files for IPO, Pitching AI-Driven Drugs
Generate:Biomedicines, the Flagship Pioneering‑backed AI drug‑discovery startup, filed for an initial public offering just nine days after dosing its first patient in a Phase 3 trial. The company has positioned itself as a leading, heavily funded player in the emerging AI‑bio...
FTC Settles Insulin Lawsuit with Express Scripts
The Federal Trade Commission reached a settlement with pharmacy‑benefit manager Express Scripts over its handling of insulin rebates, securing an agreement that extends across virtually every segment of the company’s operations. The deal requires changes to rebate structures, increased transparency,...
AbbVie Says Immunology Blockbusters Will Be 'Main Drivers' Of Growth Post-Humira
AbbVie announced that its newer immunology drugs are compensating for the imminent loss of Humira’s patent protection. The combined sales of Skyrizi and Rinvoq have already surpassed Humira’s historic peak, signaling a successful transition to next‑generation biologics. The company frames...
Rare Pediatric PRV Program Reauthorized Until 2029 via Government Funding Law
President Donald Trump signed a government funding extension that also reauthorizes the FDA’s rare pediatric priority review voucher (PRV) program through 2029. The legislation revives the incentive mechanism that awards vouchers to sponsors of approved treatments for rare pediatric diseases,...
Midi Health Raises $100M as It Plans Expansion Into Urgent Care, Research
Midi Health, the pandemic‑born women’s health platform, announced a $100 million financing round that pushes its valuation past the $1 billion unicorn threshold. The capital, led by a consortium of venture firms, will fund the launch of a nationwide urgent‑care network and...
Hims Adds Grail's Cancer Test Amid Questions About Widespread Use
Hims & Hers, the telehealth consumer‑health brand, announced a partnership with Grail to offer the Galleri multi‑cancer early‑detection blood test on its platform. The move brings a technology that can screen for more than 50 cancer types to a broader,...
Novartis Says Generics to Erode $4B From 2026 Sales
Novartis announced that generic competition will erode about $4 billion from its 2026 sales, primarily affecting three blockbuster drugs. The heart‑failure medication Entrezto, its top seller, will see its first generic entry in the fourth quarter of 2026. The company warned...
Lilly Beats Sales Forecasts, Plots Major Growth in 2026 in Stark Contrast to Novo
Eli Lilly reported fourth‑quarter 2025 revenue that topped analysts’ forecasts, signaling a stronger‑than‑expected performance. The company also projected a sizable revenue increase for 2026, driven by upcoming product launches and an expanding oncology pipeline. This upbeat guidance contrasts sharply with Novo Nordisk’s...
Embattled Novo Nordisk Considers Buying a Monthly GLP-1 to Bolster Portfolio
Novo Nordisk is actively exploring the acquisition or internal development of a long‑acting, once‑monthly GLP‑1 therapy. The move aims to counter Pfizer’s newly launched monthly obesity injection and to broaden Novo’s weight‑loss portfolio. Executives see a monthly formulation as a...
FDA Seeks Withdrawal of Amgen's Tavneos, Company Says It Won't Pull Drug
The U.S. Food and Drug Administration has formally asked Amgen to withdraw its rare‑disease therapy Tavneos from the market, citing unresolved safety and manufacturing concerns. Amgen’s CEO Bob Bradway publicly rejected the request, stating the company will continue to sell...
Novo Expects Sales to Fall in 2026, Triggering Selloff
Novo Nordisk announced it expects sales to decline by at least 5% in 2026, marking the first projected contraction in years. The slowdown is driven by adverse pricing dynamics, notably the U.S. government’s new price caps on GLP‑1 therapies. The...
'Turning Around the Titanic': How the Incoming PBM Reforms Will Transform CMS
The Centers for Medicare & Medicaid Services (CMS) is set to roll out sweeping pharmacy‑benefit‑manager (PBM) reforms that will impose transparency, rebate‑disclosure, and reporting requirements on the industry. The rulemaking, slated for finalization in early 2025, targets the opaque pricing...
China Startup AccurEdit Raises $75M for Gene Editing Therapies
AccurEdit, a Chinese biotech startup, closed a $75 million Series B round to accelerate its CRISPR‑based gene‑editing therapies. The funding, led by Hillhouse Capital and Sequoia China, will finance IND‑enabling studies and scale GMP manufacturing. Early preclinical data show over 90 percent editing...
Daiichi Ends Work on an ADC; Layoffs at GSK's R&D Unit
Daiichi Sankyo announced it is terminating development of its antibody‑drug conjugate (ADC) program aimed at solid‑tumor indications, citing strategic reprioritisation and cost considerations. The cancellation eliminates an estimated $200 million of projected R&D spend. Meanwhile, GlaxoSmithKline disclosed a reduction of roughly...
Pfizer Takes $4.4B Charge Related to Cancer Drug in Fourth-Quarter Earnings
Pfizer reported fourth‑quarter earnings that included a $4.4 billion non‑cash charge tied to a recent high‑profile cancer‑drug acquisition. The write‑down lowered net income but the company highlighted a positive Phase III readout for a separate oncology candidate. Management said the data could...
Pfizer’s Metsera-Originated Monthly GLP-1 Cuts Weight by 10.5% at Six Months
Pfizer announced that its monthly GLP‑1 obesity drug, originated from the Metsera acquisition, achieved an average 10.5% weight reduction after six months in a late‑stage study. The therapy’s once‑monthly dosing is designed to improve patient adherence compared with weekly injectables....